Expert Q&A: Addressing the Survivorship Gap in Pediatric Hodgkin Lymphoma
Refining primary treatment and emphasizing secondary treatment can help mitigate the survivorship gap faced by many pediatric survivors of HL.
Hematologic Cancer
HEMATOLOGIC CANCER ADVISOR
FEATURED CONTENT
-
-
FDA Proposal Threatens Transparency on Cancer Drug Safety and Efficacy
FDA documents have been a trove of information for researchers, leading to new insights about the safety and efficacy of a drug. An FDA proposal could end that. -
Assessing Novel Therapies in HIV-Positive Patients With Cancer
Evidence is emerging about the safety and efficacy of CAR-T therapy and CRISPR-based editing techniques in cancer patients with HIV. -
Why Cardiac Toxicity Should Not Prevent the Use of Ibrutinib for CLL or SLL
Final results of a landmark trial confirm the efficacy of ibrutinib for CLL and SLL—and while cardiovascular issues remain a concern, the benefits appear to outweigh the risks. -
VTE Risk and Incidence in Hospitalized Patients With Blood Cancers
A new study aims to address the conundrum of coagulation risk in patients hospitalized for hematologic malignancies.
HEMATOLOGIC CANCER NEWS
Gastrointestinal Involvement May Be a Sign of Waldenström Macroglobulinemia
Survival Outcomes Associated With Infusion Reactions With Rituximab in Diffuse Large B-Cell Lymphoma
No Influence of Measurable Residual Disease on Haploidentical Transplantation Outcomes in AML
Triple-Drug Induction Therapy Yields Sustained Responses in Multiple Myeloma
RBC Count, Erythrocyte Sedimentation Rate May Be Useful Biomarkers of Polycythemia Vera
Want to read more?
Please login or register first to view this content.
Next post in Hematologic Cancers
